Dose-Limiting Pulmonary Toxicity With Concurrent Ipilimumab and Chemoradiotherapy Followed by Nivolumab for Stage III Unresectable NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
International Journal of Radiation Oncology, Biology, Physics
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dose Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
Int. J. Radiat. Oncol. Biol. Phys 2023 Jan 17;[EPub Ahead of Print], CL Liveringhouse, K Latifi, AG Asous, NB Lam, SA Rosenberg, TJ Dilling, GV MacMillan, AA Chiappori, EB Haura, B Creelan, JE Gray, T Tanvetyanon, MR Shafique, AN Saltos, AA Weiner, J Clarke, CR Kelsey, S Kim, JJ Caudell, TA Rose, JR Conejo-Garcia, J Li, MJ Schell, SJ Antonia, BA PerezFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.